Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019Lina van der Straten, Avinash G. Dinmohamed, Mark‐David Levin et al.|Blood Cancer Journal|2023Cited by 36
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLLLina van der Straten, Mark‐David Levin, Claudia A.M. Stege et al.|Blood|2023Cited by 27
Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J. Hengeveld, Anton W. Langerak, Matthias Ritgen et al.|Blood|2022Cited by 24
Survival continues to increase in chronic lymphocytic leukaemia: a population‐based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016Lina van der Straten, Avinash G. Dinmohamed, Mark‐David Levin et al.|British Journal of Haematology|2020Cited by 18
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemiaArnon P. Kater, Mark‐David Levin, Marinus H. J. van Oers et al.|Haematologica|2018Cited by 13